Single high-dose liposomal amphotericin based regimen for treatment of HIV-associated Cryptococcal Meningitis: results of the phase-3 Ambition-cm Randomised Trial

Authors :: Lawrence, D.S.
Meya, D.B.
Kagimu, E.
Kasibante, J.
Mpoza, E.
Rutakingirwa, M.
Ssebambulidde, K.
Tugume, L.
Rhein, J.
Boulware, D.R.
Mwandumba, H.
Alufandika, M.
Mzinganjira, H.
Kanyama, C.
Hosseinipour, MC.
Chawinga, C.
Meintjes, G.
Schutz, C.
Comins, K.
Singh, A.
Muzoora, C.
Jjunju, S.
Nuwagira, E.
Mosepele, M.
Leeme, T.
Siamisang, K.
Ndhlovu, C.E.
Hlupeni, A.
Mutata, C.
van Widenfelt, E.
Hope, W.
Lortholary, O.
Lalloo, D.G.
Loyse, A.
Chen, T.
Molloy, S.F.
Boyer-Chammard, T.
Wang, D.
Youssouf, N.
Jaffar, S.
Harrison, T.S.
Jarvis, J.N.
Source :: Journal of the International AIDS Society. July, 2021, Vol. 24 Issue S4, p70, 2 p.
Publication Year :: 2021
Abstract: Background: Cryptococcal meningitis (CM) is a leading cause of HIV-related mortality. Based on phase-II study data showing that a single high-dose of 10 mg/kg liposomal amphotericin-B (AmBisome, Gilead Sciences Inc) [...]

Subjects :: HIV seropositivity -- Complications and side effects
Amphotericin B -- Dosage and administration -- Testing
Cryptococcal meningitis -- Drug therapy
Health

Full Text Access

Tools